Grant of Options and Notification of Transactions by Persons Discharging Managerial Responsibilities
DUBLIN, Ireland, and Boston MA, March 8, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company focussed on acquiring, developing and commercializing novel treatments for rare diseases, today announces that the Remuneration Committee has approved the grant of 3,431,350 share options (
Options ) to subscribe for ordinary shares in the Company (
Shares ) under the Employee Share Option Plan 2019 (the
Plan ) to Joe Wiley, CEO, and Rory Nealon, CFO, details of which are set out in the table below.
The Options have an exercise price of US$2.804 per Share ($14.02 per ADS equivalent) (
Investegate |Amryt Pharma PLC Announcements | Amryt Pharma PLC: Amryt Announces Record FY 2020 Results
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
AFC Energy PLC (AIM:AFC) | RNS | AFC Energy Plc
proactiveinvestors.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.co.uk Daily Mail and Mail on Sunday newspapers.
The Board of SolGold (LSE and TSX code: SOLG) is pleased to advise all shareholders and interested investors of the release of the Company s interim financial results for the half year ended 31 December 2020. The interim financial report is included as part of this announcement. Further, the Board advises shareholders and interested investors that the Company s website also contains access to additional information required to be filed on SEDAR in Canada in connection with the Company s quarterly financial period ended 31 December 2020. This additional information is available in the Financial Reports section of the Investor Centre on the Company s website: www.solgold.com.au